Clinical Trial Update: QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

The QUILT-3.020 trial evaluating ALT-801 in relapsed or refractory multiple myeloma has been terminated, with results posted on 2024-06-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ALT-801

Snippet

Sponsor: Altor BioScience | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-18